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Abstract The complete amino acid sequence of the A chain of 
mistletoe lectin I was determined via Edman degradation 
sequencing of the N-terminus and tryptic and endoproteinase 
Asp-N overlapping fragments, amino acid analysis and MALDI- 
MS. The data obtained show a great homology with the chains of 
ribosome-inactivating proteins such as ricin and abrin with 111 
(abrin-a) and 103 (ricin-D) amino acid residues conserved, 
respectively. The knowledge of the primary structure of MLA 
will have a fundamental impact on elucidating the biological 
function of medically applied mistletoe lectins on a molecular 
basis. 
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1. Introduction 
During the last years, research has focused on lectins as 
therapeutically active substances present in mistletoe extracts 
[l]. Three mistletoe lectins with different sugar specificities 
(ML-I, ML-II and ML-III) have been isolated from these 
plant extracts [2]. ML-I, the P-galactoside-specific lectin 
from Viscum album, is a ribosome-inactivating protein (type 
II RIP). It consists of two different subunits, both N-glyco- 
sylated: the toxic A chain (MLA) is linked by a disulfide 
bridge to the galactose-binding lectin B chain (MLB) [3]. 
MLB (34 kDa) binds the toxin to the cell membrane and 
delivers MLA (29 kDa) into the cell cytosol where it inhibits 
protein synthesis by the same mechanism as the ricin A chain 
and other related proteins [4,5]. MLA catalytically inactivates 
60s ribosomal subunits by hydrolyzing the N-glycosidic bond 
of the adenosine residue 4324 of 28s rRNA. It has been 
proved that the galactose-binding function is also required 
for the translocation of the glycosidic subunit into the cytosol 
[6]. MLA itself is non-toxic to intact cells [I], because it has no 
means of entering eukaryotic cells in order to reach ribosomal 
substrates. 
ML-I is a component of a commercially available mistletoe 
extract with immunostimulating potency applied for the treat- 
ment of human cancer [7]. This immunomodulating capacity 
has recently been attributed to the presence of ML-I in the 
extract [8]. Regular non-toxic subcutaneous injections of op- 
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timal doses of ML-I (1 ng/kg body weight, twice weekly) yield 
enhancements of cytokine secretion in serum, significant in- 
creases in NK cell number, in phagocytic activity of granulo- 
cytes and in the number of large granular lymphocytes [7-l 11. 
These effects prove the capacity of ML-I to stimulate non- 
specific defence mechanisms. ML-I administration is also fol- 
lowed by a release of /3-endorphin in plasma [12]. P-Endor- 
phin is an oligopeptide with profound effects on the nervous 
system. Although its function has not been clarified, this and 
other peptides of the pro-opiomelanocortin family are prob- 
ably involved in general life events like mood, sleep and pain 
[13]. They act as natural painkillers or opiates and decrease 
the pain responses in the central nervous system. Conse- 
quently, ML-I treatment may induce improvement of the 
quality of life of cancer patients. 
Recently, interest in ML-I has largely increased because of 
its obvious ability to activate non-specific defence mecha- 
nisms. The general pathway(s) of activation of these mecha- 
nisms are still unknown, but specific mistletoe lectin-carbohy- 
drate (cell glycoconjugate) interactions appear to be the 
effector system involved in eliciting such an immune response 
[14]. Controlled increases of these non-specific defence mech- 
anisms may induce clinically beneficial immunomodulation in 
the treatment of cancer [7]. Accordingly, the detailed chemical 
structure of ML-I is crucial to elucidate its immunomodula- 
tory capacity and for the design of more effective therapeutic 
substances. The present study reports the complete primary 
structure of its cytotoxic subunit MLA, as the first step for the 
structural characterization of ML-I. 
2. Materials and methods 
2.1. Protein isolation 
Mistletoe extract was obtained from an aqueous suspension by 
mixing 1.0 parts of mistletoe ground material with 1.3 parts of water 
(w/v). 20 ml mistletoe extract were centrifuged at 2000 xg for 20 min. 
The supernatant was purified by filtration (Sterivex GV Filter, Milli- 
pore) and adjusted to 100 ml with peptide eluent (0.05 M 
K2HP04*3HzO in 0.15 M NaCI, pH 7.0). The solution was applied 
to an affinity chromatography column on divinyl sulfone-activated 
lactose-coupled Sepharose 4B (3 X 50 cm) to isolate ML-I from the 
mistletoe extract [15]. The column had previously been equilibrated 
and was then eluted with the same buffer. The immobilized lectin on 
the gel matrix was washed with one column volume of 5% P-mercap- 
toethanol (v/v) and incubated at room temperature overnight, where- 
by disulfide bridges linking the two chains were cleaved. After reduc- 
tion, the column was equilibrated again with peptide eluent. Column 
eluate contains free MLA, while MLB remains bound on the gel 
material. The MLB can be obtained by elution with 0.2 M lactose 
solution [3]. The fractions containing protein were pooled, dialyzed 
against deionized water and lyophilized. 
2.2. Amino acid analysis 
Amino acid composition of MLA was determined with an Eppen- 
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dorf/Biotronik LC 3000 amino acid analyzer after hydrolysis in 6 M 
HCl for 24 h at 110°C. 
2.3. Enzymatic digestion 
Digestion of MLA (4.40 mg) with endoproteinase Asp-N (sequen- 
cing grade, Boehringer Mannheim, Germany) was carried out in 50 
mM sodium phosphate (pH 8.0) containing 2 M urea at 37°C for 24 
h. Tryptic (sequencing grade, Boehringer Mannheim) digestion (7.60 
mg) was performed in 100 mM Tris-HCl buffer (PH 8.5) with up to 
1 M urea and 10% (v/v) acetonitrile for solubilization at 37°C for 18 h. 
After enzymatic digestion, a core fraction could be precipitated at pH 
4.8 by titration with 0.1 M HCl and removed from the corresponding 
reaction mixture by centrifugation. 
2.4. Fractionation of the peptides 
The acidified peptides were fractionated by RP-HPLC on a Nucleo- 
sil C1s column (4 mmX2.50 mm) and eluted by a linear gradient of 
acetonitrile containing 0.15% (v/v) TFA at a flow rate of 1 mumin. 
Fractions obtained after titration were resolubilized in 50% (v/v) for- 
mic acid and separated by RP-HPLC on a Vydac Cd column (2 
mmx 250 mm). The peptides were eluted at a flow rate of 300 Al/ 
min using the same buffer system. The UV absorbance of the peptides 
was monitored at 214 nm. All separations were done with an Eppen- 
dorf quaternary HPLC system of the series BT 9000. 
2.5. Sequence analysis 
HPLC-purified peptides (SO-200 pmol) were dissolved in 0.1% (v/v) 
TFA and spotted onto polybrene-coated filters. The amino acid se- 
quences of the peptides were determined on an automated sequencer 
(model 473A, Applied Biosystems). 
2.6. Mass spectrometi-ic analysis 
Mass spectra were obtained by matrix-assisted laser desorption io- 
nization (MALDI) mass spectrometry (Kratos, MALDI III equip- 
ment, Shimadzu, Europe). Peptides (l&50 pmol) were dissolved in 
0.1% (v/v) TFA and applied on a target. Analysis was carried out 
in cL-cyano-4-hydroxycinnamic acid matrix solution. 
3. Results 
The complete amino acid sequence of the MLA was deter- 
mined by analysis of two sets of peptides generated by diges- 
tion of the protein with trypsin and endoproteinase Asp-N, 
respectively (Fig. 1). After digestion, reaction mixtures were 
fractionated by RP-HPLC and analyzed by sequence and 
mass spectrometric analysis. The MLA contains 254 amino 
acid residues. The molecular weight calculated on the basis 
of sequence data (28 480 Da) compares well with the apparent 
molecular weight determined by SDS-PAGE (29 000 Da) [16]. 
Similarly, the amino acid composition deduced from the se- 
quence analysis coincides well with that determined by acid 
hydrolysis (Table 1). 
The primary structure of MLA could be obtained mainly 
by analysis of the tryptic peptides. After hydrolysis, a core 
fraction could be precipitated by titration with HCl at pH 
4.8. It contained two highly hydrophobic fragments (T8 and 
T20+T21) and other large peptides resulting from the incom- 
plete cleavage of the protein. These latter ones allowed the 
alignment of other shorter peptides. The first tryptic frag- 
ments could be positioned with the help of the N-terminal 
sequence of the intact MLA, which led to an unambiguous 
identification of residues l-28. Specific bond cleavages after 
residues Arg154 and Arg234 were not detected. All peptides 
were sequenced to the end. Determined amino acid sequences 
were confirmed by mass spectrometric analysis. 
Sequence analysis of fragment Tll predicted the existence 
of a potential N-glycosylation site by the seventh Edman deg- 
radation cycle, which could be confirmed by MALDI-MS 
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Fig. 1. Amino acid sequence of the MLA and sequencing strategy. 
T and D indicate peptides analyzed from trypsin and Asp-N diges- 
tions, respectively. Dots indicate unidentified residues. Only peptides 
useful for sequence and overlap determination are shown. 
analysis. The MLA contains a glycosylation site at position 
112 of the amino acid sequence. The sequence Asn112-Gly113- 
Ser114 could be identified as glycosylation pattern. The bound 
carbohydrate moiety showed a molecular weight of 1173.0 
Da, resulting from the mass difference between the observed 
mass for the fraction Tll (MH+ 2754.7 Da) and the calcu- 
lated mass from the peptide sequence (MH+ 1581.7 Da). 
The alignment of the tryptic peptides was achieved by com- 
parison with other homologous toxic lectins such as ricin and 
abrin [17,18] and confirmed by analysis of a set of overlapping 
peptides produced by cleavage with endoproteinase Asp-N. 
All peptides were completely sequenced except Dll, where 
the first 39 amino acid residues could be identified. Fragments 
Dl 1 and D14 precipitated after titration with HCl to pH 4.8, 
whereas all other peptides remained in solution at this pH 
value. Fig. 1 shows only the peptides which were useful in 
constructing the sequence. 
However, while analysis of the peptides generated by endo- 
proteinase Asp-N made it possible to confirm the predicted 
alignment of the tryptic peptides, otherwise obtained sequence 
analysis data from these two sets of peptides showed some 
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Table 1 
Amino acid composition of intact MLA 
Amino acid Residues 
Asp 
Asn 
Thr 
Ser 
Glu 
Gln 
Pro 
Gly 
Ala 
4 cys 
Val 
Met 
Ile 
Leu 
Tyr 
Phe 
His 
Lys 
Arg 
Trp 
Total 
22.2 (12) 
(10) 
20.1 (20) 
23.3 (24) 
28.2 (11) 
(17j 
13.6 (13) 
16.1 (16) 
17.0 (17) 
n.d. (1) 
17.3 (17) 
2.7 (3) 
17.3 (17) 
25.0 (25) 
11.3 (11) 
12.1 (13j 
4.1 (4) 
0.2 (0) 
21.3 (21) 
n.d. (2) 
(2541 
Numbers in parentheses are the residues determined after sequence 
analysis. n.d., not determined. 
heterogeneity. A comparison of the primary structure deter- 
mined from the endoproteinase Asp-N digestion with that 
obtained from the tryptic cleavage reveals the presence of 17 
conservative substitutions along the amino acid sequence. 
These two slightly different determined amino acid sequences 
can be due to the presence of two isoforms of the MLA. 
Observed replacements are summarized in Table 2. Some sub- 
stitutions involve two structurally closely related amino acid 
sequence residues at the same position, such as replacements 
of Glulj -+ Asp15, Phe’44 + Tyr144 or Thrz31 + Serz31, whereas 
in other cases no homology existed between them 
(ThrlS1 + Ala151 or Alals4 + GIu’~~). The most noteworthy 
substitution may be the replacement of Asn”’ + Thrn2, which 
supposes the elimination of the glycosylation signal in the 
amino acid sequence (Asn1’2-Gly113-Ser114 + Thr112-Gly’13- 
Sern4). These results provide evidence that the A chain of 
ML-I occurs in at least two isofoims, one glycosylated 
(MLA) and one non-glycosylated (MLA’). 
4. Discussion 
The goal of this work was to determine the primary struc- 
ture of the cytotoxic chain of ML-I. Sequence information 
was obtained by analysis of two sets of peptides generated 
by trypsin and endoproteinase Asp-N, respectively. Collected 
fractions after RP-HPLC separation were examined by se- 
quence and MALDI-MS analysis. The determined molecular 
masses of the fragments were in close agreement with those 
calculated from sequence analysis data (data not shown). 
MLA contains 254 amino acid residues. Examination of its 
primary structure shows the existence of only one half cystine 
residue (CYSTIC) which presents evidence that MLA contains 
no internal disulfide bonds and the two chains of ML-I are 
linked by a single disulfide bond. Furthermore, the deter- 
mined amino acid sequence of MLA encloses a potential 
site for asparagine-linked carbohydrates (Asn112-Gly113- 
Ser1i4). The presence of covalently bound sugars at this resi- 
due was confirmed by mass spectrometric analysis. A molec- 
ular weight of 1173.0 Da could be determined for the carbo- 
hydrate chain. 
The data presented here provide evidence that MLA also 
occurs in another isoform, non-glycosylated (MLA’). This 
finding correlates with a previous report [19], which suggested 
the existence of different isolectins of Viscum album. A com- 
parison of the obtained primary structures indicates that these 
two isoforms differ at least at 17 positions. These sequence 
heterogeneities might not alter the properties of this protein 
significantly, since the amino acid residues in both proteins 
mostly have similar characteristics. Otherwise, carbohydrates 
in glycoproteins generally play no role in their catalytic func- 
tion and therefore the absent carbohydrate chain in MLA’ 
might not modify the glycosidic activity of the protein. In 
fact, it has been proved that the recombinant ricin A chain 
expressed in E. coli has full catalytic activity [20]. One possible 
role of carbohydrates in glycoproteins could be to increase 
their solubility in water. The presented amino acid sequences 
in this paper are very similar to those recently reported for the 
amino-terminal fragments of two toxic chains of ML-I iso- 
lated by two-dimensional SDS-PAGE [21]. 
The reason why the amino acid sequences of different iso- 
forms (MLA and MLA’) were determined is not clear, but it 
has been observed that lectin amounts in mistletoe prepara- 
tions depend on the month of the mistletoe harvest [22]. Mis- 
tletoe extract composition can change according to the origin 
of the plant and the thickness of its leaves as well [23]. 
Finally, the amino acid sequence of the catalytic chain of 
ML-I was compared to those of other structurally and func- 
tionally closely related proteins like ricin and abrin [17,18]. 
These proteins are known as ribosome-inactivating proteins 
(type II RIPS) and share the same mechanism of action [5]. 
Although these plants are of a different phylogenetic origin, 
their toxic components present extensive structural similarities 
and operate as potent inhibitors of eukaryotic protein syn- 
thesis at the ribosomal level. The overall sequence comparison 
of the primary structure of the A chain of ML-I (MLA) with 
those of abrin-a (ABA) and ricin-D (RTA) shows a high 
degree of homology with 111 and 103 amino acid residues 
conserved, respectively (Fig. 2). N-terminal amino acid se- 
quences are quite variable in comparison to some internal 
Table 2 
Substitutions among the amino acid sequencences of the two iso- 
forms MLA + MLA’ 
G1u15 + Asp” 
Val@ + Ile@ 
*Asn”Z + Thrii2 
Pro1i4 + Thr114 
Asp133 --t GIu’~~ 
Gln’34 + GIu’~~ 
Thri40 -+ Ser14” 
Phe’44 + Tyr’44 
ThrlS1 + Ala15r 
Tyr17g + Asplsl 
AlalE + G~u’~~ 
Valigo * Metigo 
Ile2i8 + Pheais 
Pro223 + Ser223 
Pro224 + Thrzz4 
Thrz3i + Serz3i 
Asp235 + Ser235 
*This residue is the glycosylation site of MLA. 
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t4T.A Y E R'L RL R -VTEQTTGEEYPRFITLLR'D 26 
RTA IFPKQYPII~~TAGATVQSYTNFIRAVRG 30 
ABA SDRPI-KFSTEGATSQSYKPFIEALRE 26 
la.?% 
RTA 
ABA 
YVSSGSFSN-EIPLLRQSTIPVSDAQRBVL 
RLTTGADVRBEIPVLPNRVGLP-INQRFIL 
RLRGGL-- IEDIPVLPDPTTLQ-ERNR.YIT 
55 
59 
53 
I4rA 
RTA 
ABA 
??
VELTNQGQD-SVTAAIDVTNAXV-VAYQAG'D 
V.E L 3 N'HA -ELSVTLALDVTNAYVVGYRAGN 
VBLSNSDTE-&IEVGIDVTNAXVVAXR~GT 
84 
SS 
82 
l&A 
RTA 
ABA 
QS~YFLR-DAPRGAE--TBLFTGTTR----- 
~S~~PF.PDNQEDAAAIT~L~T---'- -DVQNR 
Q S'Y P L.R -OARS S iS D Y --LPTh+--D-QB- 
106 
114 
105 
HLA 
RTA 
ABA 
??
S&LPFvlYPD-LBRYAGa--FDQIFLG-- 
YTFA'FGGNY-DRL.PQLAG-NLRENIELGNG 
-SLPFYGTYG.D-,LE'RWA-HQSRQQI-PLGLQ 
131 
142 
132 
nLA 
RTA 
ARA 
MLA 
RTA 
ABA 
IGA 
RTA 
AEA 
MLA 
RTA 
ABA 
l&A 
RTA 
ABA 
-IDQLXQSVTAL,--RFPGG---STRTQARS 155 
P L E E A:=‘- --SA'LYYYSTGGTQLPTLA--.2's 167 
A L T H G 1‘- --SFF- -RS-GGNDNELXA--:R'T 154 
. . 
I L I'L I Q.ti-i'S'i i.A'R.'FN P.1 L W R-Y ii-Q Y I N S GA S 
B I I C:i.Q~‘M’T:S”E.“A’A”RF Q Y 1. E G i M R T R 1. R Y i RR 
L 1 v I,‘2 'Q-'j4.'V"A E'A d R p R y t s N R v R V s I Q T 0 T A 
185 
197 
184 
. 
FLi'.D.VYHLSLETSWQQQSTQVQB,,ST-DGVF 
SAP'DPSVITtBN'SbORLSTAIQESNQGA-F 
~Q'PDAAHISLENNWDNLSRGV'QESVQDT-'F 
214 
226 
213 
NNPIRL- AIPPGNF-V- TLTNVROV-I--A 238 
___ - -ASPIQLQRR -F]KFSVYDVSILIP 251 
PNQVTtTNIRNlPVIVDSLSHPT-v----A 238 
SLAIHLBVCGERPSSS 254 
IIALXVYRCAPPPSSQP 267 
VLALYLFVCNPPN 251 
Fig. 2. Comparison of amino acid sequences of some ribosome-inactivating proteins (type II RIPS). MLA is the ML-I A chain. RTA is the ri- 
tin-D A chain [16] and ABA is the abrin-a A chain [17]. Sequences are aligned to maximize their similarities. Conserved residues among these 
proteins are highlighted. N-Glycosylation sites are boxed. Residues involved in the active site of the protein are marked with an * at the top of 
the column. 
regions appearing as the most rigorously conserved parts of 
these molecules (over 80% identity between residues 69-83, for 
example). 
A more extensive comparison after performing sequence 
alignment reveals that the amino acid sequence of the MLA 
conserves a number of absolutely invariant residues in the 
inhibitor protein family [24], which are presumably required 
for the catalytic function of the protein. These are Tyr76, 
Tyr115, G1u”j5, Arg’@ and Trplgg (Fig. 2). Other highly con- 
served residues, Asn74, Arglz5, Glnl’jl and Glul”, are also 
present. Their function remains to be elucidated, but they 
are believed to be less involved in maintaining the active site 
tified in the amino acid sequence of the non-glycosylated form 
(MLA’). This seems to suggest that these functionally related 
proteins have arisen from a process of divergent evolution 
from a common ancestor, since they present an essentially 
identical arrangement of amino acid residues at the active site. 
References 
[l] Franz, H. (1985) in: Lectins: Biology, Biochemistry, Clinical 
Biochemistry (Bsg-Hansen, T.C. and Breborowicz, J., Eds.) 
Vol. IV, pp. 463472, Walter de Gruyter, Berlin. 
[2] Franz, H., Ziska, P. and Kindt, A. (1981) Biochem. J. 195, 481- 
ARA 
structure [25]. All residues mentioned above can also be iden- [3] Franz, H., Ziska, P. and Kindt, A. (1982) in: Lectins: Biology, 
M. Huguet Soler et al.IFEBS Letters 399 (1996) 153-157 
Biochemistry, Clinical Biochemistry (Bog-Hansen, T.C., Ed.) 
Vol. II, pp. 171-176, Walter de Gruyter, Berlin. 
[4] Endo, Y., Tsurugi, K. and Franz, H. (1988) FEBS Lett. 231, 
378-380. 
[5] Barbieri, L., Batelli, M.G. and Stirpe, F. (1993) Biochim. Bio- 
phys. Acta 1154, 237-282. 
[6] Joule, R.J. and Neville, D.M. (1982) J. Biol. Chem. 257, 1598- 
1601. 
[7] Beuth, J., Ko, H.L., Gabius, H.-J., Burrichter, H., Oette, K. and 
Pulverer, G. (1992) Clin. Invest. 70, 658-661. 
[8] Hajto, T., Hostanska, K. and Gabius, H.-J. (1989) Cancer Res. 
49, 48034808. 
[9] Beuth, J., Ko, H.L., Tunggal, L., Geisel, J. and Pulverer, G. 
(1993) Arzneim.-Forsch./Drug Res. 43, 166169. 
[lo] Hajto, T., Hostanska, K., Frei, K., Rordorf, C. and Gabius, 
H.-J. (1990) Cancer Res. 50. 3322-3326. 
[l l] Beuth: J., Ko, H.L., Tunggal, L., Buss, G., Jeljaszewicz, J. and 
Pulverer, G. (1994) Arzneim.-Forsch./Drug Res. 44 (II), Heft 11, 
[12] Heiny, B.-M. and Beuth, J. (1994) Anticancer Res. 14, 1339- 
1342. 
[13] Falconer, J., Chan, E.C. and Madsens, G. (1988) J. Endocrinol. 
118, 5-8. 
[14] Beuth, J., Ko, H.L. and Pulverer, G. (1994) Dtsch. Apoth. Z. 25, 
17-28. 
[15] Ziska, P., Franz, H. and Kindt, A. (1978) Experientia 34, 123- 
124. 
157 
[16] Olsnes, S., Stirpe, F., Sandvig, K. and Pihl, A. (1982) J. Biol. 
Chem. 257. 13263-13270. 
[17] Halling, K:C., Halling, A.C., Murray, E.E., Ladin, B.F., Hous- 
ton, L.L. and Weaver, R.F. (1985) Nucleic Acids Res. 13, 8019- 
8033. 
[18] Hung, C.-H., Lee, M.-C., Lee, T.-C. and Lin, J.-Y. (1993) J. Mol. 
Biol. 229, 263-267. 
[19] Juther, P., Theise, H., Chatterjee, B., Karduck, D. and Uhlen- 
bruck, G. (1980) Int. J. Biochem. 11, 429435. 
[20] O’Hare, M., Roberts, L.M., Thorpe, P.E., Watson, G.J., Prior, 
B. and Lord, J.M. (1987) FEBS Lett. 216, 73-78. 
[21] Gabius, S., Kaiser, K. and Gabius, H.-J. (1991) Dtsch. Zschr. 
Onkol. 5, 113-119. 
[22] Franz, H., Ziska, P. and Kindt, A. (1985) in: Lectins: Biology, 
Biochemistry, Clinical Biochemistry (Bog-Hansen, T.C. and Bre- 
borowicz, J. Eds.) Vol. IV, pp. 473480, Walter de Gruyter, 
Berlin. 
[23] Luther, P. and Becher, H. (1987) Die Mistel: Botanik, Lektine, 
medizinische Anwendung, Springer-Verlag, Berlin. 
1241 Lord, J.M., Roberts, L.M. and Robertus. J.D. (1994) FASEB 8. _ - 
201-208. 
\ I  
[25] Betsy, J.K., Collins, E.J. and Robertus, J.D. (1991) Proteins 
Struct. Funct. Genet. 10, 251-259. 
